Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGF816 or INC280 in combination with Nivolumab in NSCLC
2014-003731-20Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab, nazartinib and capmatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Novartis. Primary endpoint: Progression-free survival rate. Started Jan 2015; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-003731-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003731-20.